Home/ Stocks/ RLMD

Relmada Therapeutics, Inc. Common Stock

RLMD XNAS

$4.94 -0.43 (-8.01%) ▼ 15-min delayed

Open

$5.45

High

$5.55

Low

$4.87

Volume

2.13M

Market Cap

$563.78M

About Relmada Therapeutics, Inc. Common Stock

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 17 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-19,051,956	$-0.22
FY 2025	$0	$-57,385,163	$-1.45
Q3 2025	$0	$-10,091,496	$-0.30
Q2 2025	$0	$-9,866,442	$-0.30

Related Market News

No specific coverage for RLMD yet. Check out our latest market news or earnings calendar.

Get RLMD Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Relmada Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.